SAMUEL LYNCH, DMSc, DMD, was a pioneer in regenerative medicine before regenerative medicine was a buzz word. He is one of the world’s foremost authorities on the use of growth factors for tissue regeneration. He has over 250 publications and patents, given hundreds of lectures in over 25 countries and is the lead Editor on two textbooks on tissue engineering and growth factors. He holds two doctorates, one from Harvard Medical School (DMSc), where he has received the Distinguished Alumnus award. His patented combinations of highly pure recombinant platelet-derived growth factor (PDGF) and tissue specific biomaterials have been successfully tested in phase 1, 2 and 3 FDA randomized, blinded, controlled clinical trials and have received the highest level of FDA approval four (4) times for regeneration of skin, bone, gingiva and mucosa. These PDGF therapies have been used in the treatment of over 5 million patients. There is no one in the field of aesthetics around the world that can match this track record of success in regenerative medicine. While he thinks of himself first and foremost as a translational scientist, he is also a highly successful serial biotech CEO and company founder in the regenerative medicine field and has been recognized as one of the individuals with the greatest impact on advancement of biologic medicines in the United States. Most recently he is the Founder and CEO of Lynch Regenerative Medicine, which recently launched sales of ariessence pure PDGF+ for use in aesthetic medicine.